Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521438 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
A Phase 2 study of Netherton Syndrome, sponsored by Quoin Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT05521438: Active Phase 2 study of Netherton Syndrome, sponsored by Quoin Pharmaceuticals.
NCT05521438 is a Phase 2 study of Netherton Syndrome that is active but no longer recruiting, run by Quoin Pharmaceuticals. The registered enrollment target is 30 participants, above the 24-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (25% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05521438, a Phase 2 study of Netherton Syndrome, is active but no longer recruiting, sponsored by Quoin Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle
Primary Outcome
Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline. The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG QRX003-2% Lotion
- DRUG QRX003-4% Lotion QAM
- DRUG QRX003-4% Lotion BID
Study Locations (5)
California
- Site #1 - San Diego
Indiana
- Site #4 - Indianapolis
Massachusetts
- Site #5 - Quincy
South Carolina
- Site #3 - Charleston
Texas
- Site #2 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05521438 still lists
NCT05521438 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, above the 24-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Netherton Syndrome appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT05521438 lists 5 locations in 5 states (California, Indiana, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05521438 about?
NCT05521438 is a clinical study titled "Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome". This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle
What is the current status of trial NCT05521438?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-06-23. Estimated completion is 2026-12-31.
What conditions does trial NCT05521438 study?
This clinical trial studies the following conditions: Netherton Syndrome.
What interventions are being tested in trial NCT05521438?
The interventions under investigation include: Vehicle (DRUG), QRX003-2% Lotion (DRUG), QRX003-4% Lotion QAM (DRUG), QRX003-4% Lotion BID (DRUG).
Who is sponsoring clinical trial NCT05521438?
This trial is sponsored by Quoin Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05521438 being conducted?
This trial has 5 study locations across California, Indiana, Massachusetts, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Netherton Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
COMPLETED · Phase 2
-
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
RECRUITING · Phase 1
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
RECRUITING · Phase 1
-
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI